Aldeyra Therapeutics, Inc.
corporate_fare Company Profile
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for ALDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for ALDX spans 8-K, 10-Q, 4, 10-K.
Recent high-impact activity:
- Aldeyra Gets Nasdaq Bid-Price Notice, Has Until May 17, 2027 to Reclaim $1.00
- Aldeyra Seeks FDA Division Transfer for ADX-2191, Withdraws Agreed SPA Protocol
- Aldeyra Q3: Cash Down to $41M, Loss Narrows, FDA Appeal Pending
- Aldeyra to Appeal FDA Rejection of Reproxalap via Formal Dispute Resolution Request
- Aldeyra Charts a Path to reproxalap NDA Resubmission Following FDA Type A Meeting
Financial Snapshot
Short Interest & Short Volume
3.44 days to coverFINRA reported short interest of 3,159,816 shares in ALDX as of the October 30, 2026 settlement, a 0.8% decrease from the prior period — about 3.4 days to cover at its recent average daily volume. On November 20, 2026, 53.2% of ALDX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.